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Abstract
Chronic granulomatous disease (CGD) is an inherited disorder of the
innate immune system characterized by a defective oxidative burst of
phagocytes and subsequent impairment of their microbicidal activity.
Mutations in one of the NADPH-oxidase components affect gene
expression or function of this system, leading to the phenotype of
CGD. Defects in gp91-phox lead to X-linked CGD, responsible for
approximately 70% of CGD cases. Investigation of the highly hetero-
geneous genotype of CGD patients includes mutation analysis, North-
ern blot or Western blot assays according to the particular case. The
aim of the present study was to use reverse transcription (RT)-PCR for
the analysis of molecular defects responsible for X-linked CGD in
eight Brazilian patients and to assess its potential for broader applica-
tion to molecular screening in CGD. Total RNA was prepared from
Epstein B virus-transformed B-lymphocytes and reverse transcribed
using random hexamers. The resulting cDNA was PCR-amplified by
specific and overlapping pairs of primers designed to amplify three
regions of the gp91-phox gene: exons 1-5, 3-9, and 7-13. This strategy
detected defective gp91-phox expression in seven patients. The RT-
PCR results matched clinical history, biochemical data (nitroblue
tetrazolium or superoxide release assay) and available mutation anal-
ysis in four cases. In three additional cases, RT-PCR results matched
clinical history and biochemical data. In another case, RT-PCR was
normal despite a clinical history compatible with CGD and defective
respiratory burst. We conclude that this new application of RT-PCR
analysis - a simple, economical and rapid method - was appropriate for
screening molecular defects in 7 of 8 X-linked CGD patients.
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Introduction
Chronic granulomatous disease (CGD)
is a primary immunodeficiency originally
described in 1957 as a clinical entity affect-
ing male infants and named, at the time, fatal
granulomatous disease of childhood. The
main characteristics of CGD are recurrent
and severe infections involving the natural
barriers of the organism such as the respira-
tory tract and lymph nodes, and eventually
inner structures such as the liver, spleen,
bones, and brain (1-3). The estimated inci-
dence of this rare disease is 1/250,000 live
births per year. The infections are generally
caused by catalase-negative bacteria such as
Staphylococcus aureus, Gram-negative ba-
cilli, and fungal species such as Aspergillus,
Candida and Nocardia (4,5).
The NADPH-oxidase system generates
superoxide and other reactive oxygen inter-
mediates, crucial for the microbicidal activ-
ity of phagocytes. The biochemical defect in
CGD is an impairment of NADPH-oxidase
activity and subsequent inability to destroy
microorganisms (6). The main components
of the NADPH-oxidase system are gp91-,
p22-, p47-, p67-, and p40-phox. Molecular
defects causing CGD are generally due to
absence, low expression or malfunctioning
of one of the NADPH-oxidase components.
The X-linked form of this disease is caused
by defects in gp91-phox, the heavy chain of
cytochrome b588, and accounts for approxi-
mately 70% of all cases (7,8). The autosomal
recessive forms are caused by defects in one
of the cytosolic components of NADPH oxi-
dase (p47- or p67-phox, respectively in 20
and 5% of cases), or the cytochrome b588
light chain component (p22-phox, 5% of
cases) (9,10). CGD is a highly heteroge-
neous condition: over 300 mutations have
been registered in an internationally main-
tained X-CGD database (8). The mutations
have been distributed largely within the 13
exons or at the exon/intron boundaries of the
gp91-phox (CYBB) gene and almost 200 of
these mutations are unique.
The diagnosis of CGD is generally based
on the clinical characteristics of the disease
plus defective NADPH-oxidase activity as
demonstrated by abnormal nitroblue tetrazo-
lium (NBT), dihydrorhodamine 123, or su-
peroxide release assays (11,12). In the
stimulated NBT test, normal individuals dis-
play nearly 100% positive cells, while in
CGD patients fewer than 5% of the cells are
positive (13). In addition, cells from patients
with variant CGD are positive, but show
only very low activity (6). The NBT test also
detects the carriers of X-linked CGD (moth-
ers and sisters). A definitive molecular CGD
diagnosis is established in patients with an
abnormal NBT test or respiratory burst ac-
tivity who have one of the following charac-
teristics: a mutation in gp91-, p22-, p47-, or
p67-phox; absent mRNA for one of these
genes detected by Northern blot analysis;
and/or absent protein for one of these oxi-
dase components by Western blot. A ge-
netic, but not molecular, diagnosis can be
established by demonstration of maternal
cousins, uncles, or nephews with an abnor-
mal NBT test or respiratory burst (14). Thus,
the establishment of a definitive diagnosis of
this rare and highly heterogeneous disease
requires complex and expensive methodolo-
gies such as a combination of Northern blot
or Western blot, and single-strand confor-
mation polymorphism analysis (SSCP) fol-
lowed by DNA sequencing of several family
members, all performed in high complexity
research laboratories.
The reverse transcription-PCR (RT-PCR)
method involves the amplification of cDNA
by PCR. This technique can be easily stan-
dardized in less sophisticated laboratories. It
provides information about gene expression
and preliminary data about the structure or
size of the mRNA of the defective compo-
nent. RT-PCR has seldom been used in CGD
research, being limited to pathophysiology
studies (15-29). To date, the potential use of
this useful tool for establishing the definitive
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diagnosis of X-linked CGD, the most fre-
quent form, has not been extensively investi-
gated. The aim of the present study was to
evaluate the use of RT-PCR for screening
molecular defects responsible for X-linked
CGD, a rare and possibly misdiagnosed im-
munodeficiency, in eight Brazilian patients.
Patients and Methods
Patients
The study included 8 unrelated male Bra-
zilian patients with probable X-linked CGD
(2 Blacks and 6 Caucasians; age 2-8 years;
height 88-108 cm; weight 11-19 kg). The
patients presented clinical histories of recur-
rent severe infections such as pneumonia,
lymphadenitis, liver abscess, pyodermitis,
and adverse reactions to BCG immuniza-
tion. They were referred to our laboratory for
biochemical and molecular diagnostic evalu-
ation. Written informed consent was ob-
tained from the participants prior to the study.
The Medical School Ethics Committee ap-
proved the protocol in accordance to the
Helsinki Convention and Brazil Ministry of
Health, Resolution 196/96.
Biochemical diagnosis of CGD
The biochemical diagnosis of CGD was
established according to the Pan American
Group for Immunodeficiencies criteria. An
impairment of NADPH-oxidase activity was
demonstrated by the NBT slide test and/or
the superoxide anion release assay by pe-
ripheral blood neutrophils and mononuclear
leukocytes (14,30,31). Neutrophils and
mononuclear leukocytes were obtained by
centrifugation of blood samples over a Ficoll-
Hypaque density gradient (32).
The NBT slide test was based on the
reduction of NBT to formazan by activated
leukocytes (31). The assay was performed as
previously described (30). More than 95%
of 200 normal neutrophils stimulated with
30 nM phorbol 12-myristate 13-acetate
(PMA) should be able to reduce NBT. Ab-
sent reaction or <5% positive cells was con-
sidered to indicate a diagnosis of CGD (14).
Quantitative superoxide release by neu-
trophils and mononuclear leukocytes was
assessed by a modified superoxide dismu-
tase-inhibitable cytochrome c reduction as-
say (33-35). The amount of superoxide re-
leased was calculated using an extinction
coefficient of 0.21 nM/cm for cytochrome c.
The results are reported as nmol superoxide
released by 106 cells per hour. Patients with
CGD showed less than 10% of control values.
Screening molecular defects responsible for
X-linked CGD
B-lymphocytes from X-linked CGD pa-
tients were transformed in vitro with Epstein
B virus (EBV) (15,16) in order to provide an
abundant source of nucleic acids for molec-
ular studies. The EBV-transformed B cell
lines reproduce the biochemical and molec-
ular defects of CGD patients (15,16,36), and
eliminate the need for repeated blood collec-
tions. Briefly, peripheral blood leukocytes
from X-linked CGD patients were cultured
with supernatants from B95-8, an EBV-pro-
ducer cell line (15,16,36,37), in RPMI 1640
medium supplemented with heat-inactivated
fetal bovine serum (10%), 2 mM L-gluta-
mine, 100 U/ml penicillin, and 100 µg/ml of
streptomycin, at 37ºC, in a humid atmos-
phere with 5% CO2. Cell viability was moni-
tored and the cultures were maintained
throughout the study period.
RNA samples from EBV-transformed B-
cell lines were prepared by the guanidine
HCl method, followed by ethanol precipita-
tion and quantification by standard methods
(38,39). The cDNA samples were obtained
by reverse transcription of 2 µg of total RNA
with SuperScript II RT (GIBCO BRL) and
random hexamers (15). The quality of the
mRNA samples was checked by PCR ampli-
fication of ß-actin, a constitutive gene con-
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trol (bp 920-943 and bp 1494-1471) (Gen
Bank accession No. NM001101).
gp91-phox gene expression was assessed
by RT-PCR. Specific and overlapping pairs
of primers (Gen Bank accession No.
NM_000397, Table 1) were used to amplify
(30 cycles) three gp91-phox exonic regions:
1-5, 3-9, and 7-13. This strategy permitted us
to screen all gp91-phox exons. PCR prod-
ucts were analyzed by 2% agarose gel elec-
trophoresis and stained with ethidium bro-
mide.
Relative gp91-phox gene expression was
analyzed with the Image Master Software
(Pharmacia-Biotech). The densitometry re-
sult for target samples was divided by the
densitometry result of ß-actin, a constitutive
gene control, normalizing the level consid-
ered for analysis. The results of RT-PCR
assays were compared to patient clinical his-
Table 1. Oligonucleotide primers used for gp91-phox RT-PCR analysis.
Region Sequence of gp91-phox primers
Forward Reverse
Exons 1-5 5'-GCT CTA GAG CAT GAG GGG  CTC 5'-CGG GAT CCC GAG TTC AGA GAG
TCC ATT TTT GTC A-3' TGC TAC TGA ATA A-3'
Exons 3-9 5'-GCC TGC CTG AAT TTC AAC-3’ 5'-TCA TCT GTA GCT CGA TG-3'
Exons 7-13 5'-GGA ATG CCC AAT CCC TCA G-3' 5'-GGG CCA GAC TCA GAG TTG  G-3'
Table 2. Stimulated respiratory burst activity of granulocytes (GRA) and mononuclear leukocytes (MON) as
assessed by the nitroblue tetrazolium (NBT) test or superoxide release assay, and gp91-phox gene expres-
sion in Epstein B virus-transformed B lymphocytes from patients with chronic granulomatous disease as
assessed by RT-PCR analysis.
Patient Respiratory burst activity Relative gp91-phox expression
NBT Superoxide Exons 1-5 Exons 3-9 Exons 7-13
1. G.M. MON 1.0 Reduced Reduced Absent
2. R.B. <5% Reduced Reduced Reduced
3. G.G. <5% Possible splicing defect Absent Absent
4. T.P.B. <5% MON 0.27 Normal expression Normal expression Normal expression
GRA 0.22
5. M.F. <5% GRA 0.22 Normal expression Reduced Reduced
6. T.P. <5% MON 0.25 Normal expression Reduced Absent
GRA 0.46
7. R.S. MON -0.03 Possible splicing defect Absent Reduced
GRA 0.58
8. J.E.M. <5% MON 0.0 Absent Absent Absent
GRA 0.3
NBT is reported as percent of positive cells. Normal individuals display nearly 100% positive cells. GRA and
MON from healthy controls released superoxide in the range of 6-14 and 5-7 nmol O2- 106 cells-1 60 min-1,
respectively.
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tory, biochemical assays (NBT and/or super-
oxide release assay), and available mutation
analysis data (http://www.sbi.org.br/Sbi2003/
index.htm).
Results
We studied 8 male patients with clinical
histories of recurrent severe infections, re-
ferred to our laboratory for biochemical and
molecular diagnosis of CGD. The results of
the NBT slide tests and the superoxide re-
lease assays are shown in Table 2. Six of the
patients presented less than 5% positive leu-
kocytes in the NBT slide test. Six patients
showed impaired superoxide release by
granulocytes and/or mononuclear leukocytes
(less than 10% compared to healthy con-
trols). Four patients had abnormal results in
both tests. All patients presented at least one
abnormal test and received the diagnosis of
probable X-linked CGD. The mother and the
sister of patient T.B.P. presented an NBT
slide test compatible with the carrier status
of X-linked CGD. During the study period
Figure 1. RT-PCR analysis of gp91-phox gene expres-
sion (exons 1-5) in Epstein B virus-transformed B cells
from patients with X-linked chronic granulomatous dis-
ease. Representative 2% agarose gel electrophoresis
of PCR products stained with ethidium bromide. Size
standards (100-bp ladder); Lane 1, patient G.M.; lane 2,
patient R.B.; lane 3, patient G.G.; lane 4, patient T.P.B.;
lane 5, patient M.F.; lane 6, patient T.P.; lane 7, patient
R.S.; lane 8, patient J.E.M., and lane 9, healthy control.
ß-actin was used as an internal control for RT-PCR in all
samples. The lower panel shows the mean band densi-
tometry of gp91-phox/ß-actin relative expression (N =
3).
one patient (G.M.) died from pneumonia.
We next investigated the definitive diag-
nosis of X-linked CGD by RT-PCR analysis
of gp91-phox gene expression. The results
of RT-PCR amplification with three sets of
overlapping primers are presented in Table
2. The quality of the mRNA sample was
checked by PCR amplification of ß-actin, a
constitutive gene control. The expected nor-
mal products were obtained in this case (Fig-
ures 1, 2 and 3).
The amplification of exons 1-5 detected
two patients (G.M. and R.B.) with reduced
gp91-phox gene expression (Figure 1, lanes
1 and 2, respectively). One patient (J.E.M.,
lane 8) showed absent gp91-phox gene ex-
pression. Two patients (G.G. and R.S.; Fig-
ure 1, lanes 3 and 7, respectively) presented
a smaller PCR product (between 300 and
400 bp), suggesting a splicing defect or small
deletion. Three patients presented normal
gp91-phox expression (T.P.B., M.F. and T.P.;
Figure 1, lanes 4, 5, and 6, respectively).
The results of RT-PCR amplification of
gp91-phox exons 3-9 are presented in Figure
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Figure 2. RT-PCR analysis of gp91-phox gene
expression (exons 3-9) in Epstein B virus-trans-
formed B cell lines from patients with X-linked
chronic granulomatous disease. Representa-
tive 2% agarose gel electrophoresis of PCR
products stained with ethidium bromide. Size
standards (100-bp ladder); Lane 1, patient G.M.;
lane 2, patient R.B.; lane 3, patient G.G.; lane 4,
patient T.P.B.; lane 5, patient M.F.; lane 6, pa-
tient T.P.; lane 7, patient R.S.; lane 8, patient
J.E.M., and lane 9, healthy control. ß-actin was
used as an internal control for RT-PCR in all
samples. The lower panel shows the mean
band densitometry of gp91-phox/ß-actin rela-
tive expression (N = 3).
Figure 3. RT-PCR analysis of gp91-phox gene
expression (exons 7-13) in Epstein B virus-
transformed B cell lines from X-linked CGD
patients. Representative 2% agarose gel elec-
trophoresis of PCR products stained with ethi-
dium bromide. Size standards (100-bp ladder);
Lane 1, patient G.M.; lane 2, patient R.B.; lane
3, patient G.G.; lane 4, patient T.P.B.; lane 5,
patient M.F.; lane 6, patient T.P.; lane 7, patient
R.S.; lane 8, patient J.E.M., and lane 9, healthy
control. ß-actin was used as an internal control
for RT-PCR in all samples. The lower panel
shows the mean band densitometry of gp91-
phox/ß-actin relative expression (N = 3).
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2. Two patients (R.B. and M.F.) presented
reduced gp91-phox gene expression (Figure
2, lanes 2 and 5, respectively). Three pa-
tients (G.G., R.S., and J.E.M.; lanes 3, 7, and
8, respectively) presented absent gp91-phox
gene expression. Three patients presented
normal gp91-phox expression (G.M., T.P.B.
and T.P.; Figure 2, lanes 1, 4 and 6, respec-
tively).
RT-PCR amplification of gp91-phox ex-
ons 7-13 is presented in Figure 3. One pa-
tient (R.B.) presented reduced gp91-phox
gene expression (Figure 3, lane 2). Four
patients (G.M., G.G., T.P. and J.E.M., lanes
1, 3, 6, and 8, respectively) presented absent
gp91-phox gene expression. Three patients
(T.P.B., M.F. and R.S.; Figure 3, lanes 4, 5
and 7, respectively) presented normal gp91-
phox expression.
In four cases, it was possible to match
RT-PCR data with available mutation analy-
sis, presented elsewhere by Patiño et al. (30)
or by our group (http: //www.sbi.org.br/
Sbi2003/index.htm): J.E.M. presented a
C469→T transition in exon 5, predicting a
nonsense mutation (R157X). M.F. presented
a nonsense substitution in exon 3, R (argi-
nine) 73-Stop. R.S. showed a 264 G→A
substitution at the 3' splice junction of gp91-
phox exon 3. The cDNA sequence showed a
deletion of gp91-phox exon 3, giving rise to
an unstable or nonfunctional mutant gp91-
phox. G.G. presented a defective splicing of
gp91-phox exon 3 (the underlying mutation
has not yet been determined). The other
patients continue to be under investigation.
As a whole, this strategy permitted the
detection of defective gp91-phox expression
in seven of eight patients. The RT-PCR re-
sults matched clinical history, biochemical
data (NBT or superoxide release assay) and
available mutation analysis in four cases. In
three additional cases, RT-PCR results
matched clinical history and biochemical
data. In another case, RT-PCR was normal
despite a clinical history compatible with
CGD, a defective respiratory burst charac-
terized by the NBT test and superoxide re-
lease assay and NBT tests of his mother and
sister compatible with X-linked CGD carrier
status.
Discussion
This paper reports on the biochemical
and gene expression studies of 8 unrelated
Brazilian male patients with a clinical his-
tory of CGD, who were referred to our labo-
ratory for detailed investigation. CGD is a
rare inherited disorder in which phagocytic
cells are unable to generate superoxide an-
ion and other reactive oxygen intermediates.
We initially established the diagnosis of prob-
able X-linked CGD by means of biochemi-
cal methods such as the NBT slide tests and/
or superoxide anion release assays. Our re-
sults showed that all patients presented im-
paired NADPH-oxidase function and, in turn,
probable X-linked CGD.
Both methods contribute to the probable
diagnosis of CGD in different ways. The
NBT slide test provides information about
the number of cells that reduce NBT to
formazan inside the cytoplasm and the inten-
sity of this reduction. Thus, patients with
variant forms of X-linked CGD show abnor-
mal NBT slide tests, in which most of the
cells weakly reduce NBT to formazan. The
NBT slide test also detects female carriers of
X-linked CGD. The superoxide release as-
say measures the reduction of cytochrome c
by superoxide produced by activated leuko-
cytes present in the reaction, permitting the
diagnosis of variant forms of X-linked CGD.
Both tests can be easily standardized in low
complexity laboratories and neither requires
expensive equipment. The dihydrorhodamine
123 test is a highly sensitive method for the
biochemical diagnosis of CGD; however, it
requires a flow cytometer, a very expensive
instrument.
We evaluated gp91-phox gene expres-
sion in EBV-transformed B lymphocytes
from CGD patients by RT-PCR analysis.
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Specific and overlapping pairs of primers
were used to amplify three regions of the
gp91-phox gene by RT-PCR: exons 1-5, 3-9,
and 7-13. This strategy permitted the detec-
tion of defective gp91-phox expression in 7
of 8 patients. The RT-PCR results matched
clinical history, biochemical data (NBT or
superoxide release assay) and available mu-
tation analysis in four cases. In three addi-
tional cases, RT-PCR results matched clini-
cal history and biochemical data.
gp91-phox gene expression was reduced
in all exonic regions of patient R.B. This
reduction can be the result of mutations lead-
ing to low RNA stability or altered transcrip-
tional activity. Patients G.M. and T.P. showed
absent expression of exons 7-13, suggesting
that the decreased expression of these addi-
tional 3'-end exons can be the result of RNA
instability or a splicing defect, e.g., partially
correct splicing to produce a signal, but
partially abnormal splicing to eliminate a
primer binding site, a subject to be investi-
gated by future genomic DNA mutation
analyses.
Patient G.G. presented a diffuse, low
abundance, smaller-sized product of exons
1-5 (Figure 1), and absent expression of
other exonic regions. His mutation analysis
showed a defect at the exon 3 splice site.
Similarly, the mutation analysis of patient
R.S. also revealed a defect at the exon 3
splice site. However, in this case, a less
abundant PCR product could be detected.
Patient M.F. presented reduced expres-
sion of exonic regions 3-9 and 7-13, which
can be the result of defective transcriptional
activity in exon 3. J.E.M. presented a non-
sense mutation in exon 5 that resulted in loss
of gp91-phox expression, as evidenced by
RT-PCR analysis, a possible consequence of
nonsense-mediated mRNA instability.
In one case, patient T.P.B., gp91-phox
gene expression was normal despite a family
history compatible with CGD and a defec-
tive respiratory burst activity. In this case,
the diagnosis of probable X-linked CGD
was based on abnormal NBT tests in his
mother and his sister, compatible with car-
rier status. We hypothesize that a point mu-
tation, such as a single base substitution that
does not change PCR fragment length or
abundance, should be investigated in this
particular case.
RT-PCR is a powerful tool to assess gene
expression. This characteristic may partially
explain the variability of gp91-phox gene ex-
pression among the patients included in this
study, and the importance to combine overlap-
ping pair of primers to screen the full length of
the message. RT-PCR has been used in iso-
lated case studies as part of the initial diagno-
sis of the different forms of CGD (17-22). RT-
PCR analysis was also useful in the prenatal
diagnosis of CGD, resulting from p47-phox
deficiency (23). However, it has been more
commonly used for the study of gene regula-
tion of the NADPH-oxidase components in a
variety of cells (15,16,24-29). To date, the
potential use of this useful tool for establish-
ing the definitive diagnosis of X-linked CGD,
the most frequent form, has not been investi-
gated extensively. Further studies should be
performed to compare the sensitivity and
specificity of this test compared to other
complex assays such as Western or Northern
blots.
Overall, we have demonstrated that RT-
PCR, a simple and low cost methodology,
established the definitive diagnosis of X-
linked CGD in 7 of 8 cases, without the need
to use complex and expensive methodolo-
gies such as Northern blot, slot blot, SSCP
analysis, or genomic DNA sequencing. Thus,
RT-PCR may be a suitable tool for diagnos-
ing CGD in laboratories in developing coun-
tries. It is very important to determine the
definitive molecular genetic defect in order
to provide the appropriate genetic counsel-
ing and prognosis to kindreds with CGD. In
addition, molecular genetic studies of the
human NADPH-oxidase system will advance
the knowledge about this crucial and ancient
defense mechanism.
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